iHuman
7 hedge funds and large institutions have $79.4K invested in iHuman in 2026 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0.11% less ownership
Funds ownership: 0.25% → 0.14% (-0.11%)
13% less funds holding
Funds holding: 8 → 7 (-1)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
94% less capital inflows, than outflows
Capital inflows: $4.52K | Capital outflows: $81.1K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$4.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$45.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$15.8K |
| 3 |
Credit Agricole
Montrouge Cedex,
France
|
-$14K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.87K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$149 |
IH Hedge Fund Activity: Q3 2026 in Review
7 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in iHuman (IH) for Q3 2026, worth a combined $79.4K — down 56% from $180K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of IH and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 1 added.
The largest buyer was Goldman Sachs, adding an estimated $4.52K. The largest seller was Morgan Stanley, cutting an estimated $45.3K.
- 7 institutional investors held iHuman (IH) as of Q3 2026, down from 8 in Q2 2026.
- Funds reported $79.4K of iHuman stock for Q3 2026, down 56% quarter-over-quarter.
- 0 funds opened new iHuman positions in Q3 2026 and 1 closed out, a net change of -1 holder.
- The largest iHuman buyer in Q3 2026 was Goldman Sachs, an estimated $4.52K added.
- The largest iHuman seller in Q3 2026 was Morgan Stanley, an estimated $45.3K sold.
Based on aggregated 13F filings for Q3 2026.